Thymalin

Thymalin at a Glance

Thymalin is a polypeptide fraction extracted from calf thymus, developed in the Soviet Union as an immune bioregulator and registered as a medicine in Russia. Like Cerebrolysin it is an extract rather than a defined molecule, which makes its composition a manufacturing specification rather than a chemical formula. It is injected in courses for immune support and is claimed to have geroprotective effects. It has no approval outside Russia and its literature comes largely from a single research network.

History & Development

Thymalin is not a peptide. It is an extract of calf thymus - a mixture, registered as a medicine in Russia, and impossible to characterise the way a defined molecule can be.

First described	Not established in the sources consulted for this section
Discovered / synthesised by	Not established in the sources consulted for this section
Institution	Not established in the sources consulted for this section
Origin	Calf-thymus polypeptide extract - a mixture, not a single defined molecule
Key patent	Not established in the sources consulted for this section
Assignee	Not established in the sources consulted for this section
Development status	Registered in Russia; unapproved in the West

Discovery

The thymus trains T-cells and involutes with age, so extracting its factors to restore immune function is an old and reasonable idea. Thymalin is that idea as a product: purified calf thymus, prepared as a polypeptide extract and injected as an immune bioregulator.

It shares its central limitation with cerebrolysin: it is a mixture. There is no sequence, no molecular weight and no single receptor, so identity and consistency depend on the manufacturing process rather than on chemical definition. Two batches are the same thing because they were made the same way, not because they can be shown to be identical.

It belongs to the same Soviet “bioregulator” tradition as epitalon - glandular tissue extracts developed as restorative agents for age-related decline.

Development & ownership

Thymalin is registered in Russia, where the clinical literature uses short intramuscular courses of roughly 10 mg/day for 5-10 days, repeated periodically.

What does not exist is any of the infrastructure that would let a Western reader evaluate it: no independent pharmacovigilance, no Western safety data and no long-term follow-up. It is an injected animal-tissue product, which carries considerations a synthetic peptide does not - both for transmissible agents and for anyone avoiding bovine-derived material.

How it reached the market

Thymalin is a registered prescription product in Russia and unapproved everywhere else, sold in Western grey markets as an immune and longevity injectable on the strength of small Russian studies that no independent group has repeated.

What It's Used For

Thymalin is not a molecule — it is an extract. It is a mixture of low-molecular-weight polypeptides obtained by acid extraction of calf thymus, developed from the 1970s onward by Vladimir Khavinson’s group in Leningrad/St. Petersburg and given as an injectable “immune bioregulator” ^{7Reference 7Morozov VG · 1997ReviewNatural and synthetic thymic peptides as therapeutics for immune dysfunction — review + uncontrolled human clinical useView study →}. That distinction is the spine of the whole account, and it is the same distinction that governs its sibling epitalon: epitalon is a defined synthetic tetrapeptide, whereas epithalamin is the pineal extract it was derived from, and the two are routinely conflated. Thymalin sits on the extract side of that pairing. Two short peptides isolated from it — Lys-Glu (KE) and Glu-Trp (EW) — were later developed as defined single-molecule drugs (Vilon and Thymogen respectively) ^{5,7Reference 5Linkova N et al. · 2023In vitroThe influence of KE and EW dipeptides in the composition of the thymalin drug on gene expression and protein synthesis involved in the pathogenesis of COVID-19 — in vitro (human PBMC) + in silicoView study →Reference 7Morozov VG · 1997ReviewNatural and synthetic thymic peptides as therapeutics for immune dysfunction — review + uncontrolled human clinical useView study →}, so thymalin stands in the same relation to thymogen as epithalamin does to epitalon. Being an extract has hard evidential consequences, the same ones that qualify cerebrolysin: its full composition is not characterized, there is no standardized potency assay, and batch-to-batch consistency is an open question, so “thymalin” in a 1989 paper and “thymalin” in a 2024 paper are not demonstrably the same material.

The provenance problem is severe, and it has to be stated before any result. Of the 293 records PubMed returns for thymalin, roughly 250 are Russian-language, and the overwhelming majority of the positive human and mechanistic work comes from a single affiliated research network (Khavinson and Kuznik; St. Petersburg and Chita). Much of it is not verifiable in English-language indexes, was published without the methodological reporting a Western reader would expect, and has never been independently replicated. Only what could actually be verified is cited below; unverifiable Russian-language claims are left out rather than laundered into a numbered reference. One consequence is worth sitting with: the only in-vivo studies here from a group outside the Khavinson network are two 1989–91 papers from an East German institute in Jena, and both are null ^{11,12Reference 11Baumgart J · 1991AnimalAge-dependent experimental tumor dissemination of murine melanoma B16 — animal (mouse); null result for thymalinView study →Reference 12Baumgart J et al. · 1989AnimalAge-dependent antileukemic action and suppression of immune response by ambazone in mice — animal (mouse); null result for thymalin combinationView study →}.

Route is load-bearing. Thymalin is a lyophilized powder reconstituted for intramuscular injection; as a mixture of protease-labile peptides it is not meaningfully orally active, so no oral or sublingual product can deliver what the injected courses were studied at. It is a registered prescription preparation in Russia and some neighboring states — which is not, and must not be read as, Western approval. It has no FDA or EMA authorization, and zero trials registered on ClinicalTrials.gov.

One more disambiguation, because it is the most common error in this area: thymalin is not thymosin alpha-1, thymosin beta-4, thymopentin or thymulin. Those are defined single molecules with their own (much better) literatures — thymosin alpha-1 is an approved drug in more than 30 countries, and thymosin beta-4 has run registered Phase 3 trials. Studies of those compounds are routinely mis-cited as thymalin evidence. None of their data appears here.

Evidence by IndicationStrength of support · Beta

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. For thymalin the ceiling is deliberately low — nothing clears 40% — because essentially every positive finding traces to one research network, the pivotal COVID-19 trial is unindexed and unregistered, and there are no registered trials anywhere. Read the low scores carefully: for cancer adjunct the number is low because the compound was tested and did not work in two independent rodent models, while for bone repair and radiation cytogenetics it is low because the human study has simply never been done. Each application links down to its write-up.

01COVID-19 (severe, adjunct)Shaky38%One unindexed, unregistered single-blind placebo-controlled trial (n=80) + one indexed comparative study + in-vitro mechanism — all one network, one center

02Immune restoration & immunomodulationShaky34%Consistent in-vitro human cell data + decades of uncontrolled Russian clinical use + one small human timed-dosing trial

03Anti-aging & mortality reductionShaky28%One 6–8-year study in 266 elderly people; no reported randomization or blinding; largest effect is a combination; never replicated

04Cancer immunotherapy adjunctShaky20%One positive rat sarcoma model + one uncontrolled human series, against two independent null rodent studies

05Reparative osteogenesis (bone/dental)Shaky16%Rat mandible-defect model, one lab, 2024, co-administered with a bone graft — no human data

06Radiation cytogeneticsShaky12%Ex-vivo human lymphocytes, one group — and the effect is bidirectional (protective or sensitizing)

Mechanisms

Pharmacokinetics

Thymalin’s pharmacokinetics are best described as undefined, and undefinable in the usual sense — the same problem cerebrolysin has. Because it is a heterogeneous mixture of peptides rather than a single molecule, there is no single plasma half-life, no standardized potency or identity assay, and no published ADME dataset. Its two named active dipeptides (KE and EW) would be expected to clear rapidly, as short peptides do, but that is inference from class, not a measurement of the product.

What is clear is the route. Thymalin is supplied as a lyophilized powder reconstituted for intramuscular injection, and every clinical finding here rests on that route ^{1,7Reference 1Khavinson VKh · 2003Peptides of pineal gland and thymus prolong human life — human (long-term controlled study, 266 subjects, no reported randomisation or blinding)View study →Reference 7Morozov VG · 1997ReviewNatural and synthetic thymic peptides as therapeutics for immune dysfunction — review + uncontrolled human clinical useView study →}. As a mixture of protease-labile peptides it has negligible oral bioavailability — gut proteases digest it — so oral or sublingual “thymalin” products cannot deliver the injected-course effects described above, regardless of the label. Dosing in the literature is given as short IM courses (on the order of 10 mg/day for several consecutive days, repeated periodically) rather than a single fixed dose or continuous administration ^{1Reference 1Khavinson VKh · 2003Peptides of pineal gland and thymus prolong human life — human (long-term controlled study, 266 subjects, no reported randomisation or blinding)View study →}. Reconstitution technique, sterility and cold-chain storage are therefore practical determinants of what is actually administered — and for an extract with no potency assay, they cannot be checked after the fact.

Clinical & regulatory status

Thymalin is a registered prescription preparation in Russia (Тималин) and has been used clinically there and in some neighboring states for decades under the Khavinson bioregulator program. It is not approved by the FDA or the EMA, is not an approved dietary supplement anywhere in the West, and holds no marketing authorization outside its region of origin. Russian registration is not Western approval and does not transfer — that distinction is the single most misrepresented fact about compounds in this cluster. Outside Russia and the CIS, any material circulates as unapproved gray-market product sold “for research use only.”

Registered-trial activity is absent: a ClinicalTrials.gov v2 API query for thymalin returns zero studies, and the pivotal COVID-19 randomized trial was published in a Russian gerontology journal without any trial registration and without PubMed indexing. The counts below reflect what is findable and verifiable in PubMed and English-language registries in this pass; the Russian-language literature is far larger (roughly 250 of the 293 PubMed records) but is not independently verifiable here, and is not counted as evidence.

Last checked: July 2026.

Sourcing, Route & Legal Status

Regulatory status — status before benefit. Thymalin is a registered prescription drug in Russia, dispensed there under medical supervision, and has been used in some CIS states on the same basis. It has never been approved by the FDA, the EMA, the TGA, or any comparable Western regulator, for any indication, and it is not a dietary supplement in the US, UK, EU or Australia. A registration in one country covers one product, one indication and one population under that country’s regulator; it confers nothing elsewhere, and the fact that thymalin is a real pharmacy medicine in Russia should not be allowed to imply Western legitimacy. Outside its region of registration it is an unapproved research chemical, sold “for research use only / not for human consumption.” It is not a scheduled or controlled substance, but “unscheduled” is not “approved” — marketing it for human use is unlawful in most Western jurisdictions precisely because it is unapproved.

How it’s supplied & administered. Pharmaceutical thymalin is a lyophilized (freeze-dried) powder — a mixture of low-molecular-weight calf-thymus polypeptides — reconstituted with sterile water or saline immediately before use and given by intramuscular injection in short courses. The gray market sells the same dosage form, lyophilized powder in vials for reconstitution, but community practice frequently shifts the route to subcutaneous injection by analogy with other research peptides. That is a real divergence worth naming: every clinical finding here used intramuscular dosing, and there is no bioequivalence, PK or efficacy data for subcutaneous thymalin at all. Any oral or sublingual product is pharmacologically inert regardless of the number on the label. The powder requires cold-chain storage; reconstituted material needs prompt use and sterile handling.

Sourcing reality (this is a safety issue, not a footnote). Outside Russia, thymalin reaches buyers through unregulated vendors with no manufacturing oversight, no pharmacopoeial standard, and no regulatory accountability. For this compound the identity problem is unusually acute, because thymalin is defined as a mixture, not a molecule: there is no single sequence to confirm by mass spectrometry, no potency assay, and therefore no meaningful way for a buyer — or a certificate of analysis — to establish that a vial contains thymalin at all, as opposed to some other peptide powder, a different thymic preparation, or nothing active. A COA that reports purity for a single peptide is answering the wrong question. Layered on top are the standard injectable risks: bacterial endotoxin and sterility failure, mislabeled or misdosed vials, and infection or abscess from non-sterile reconstitution. It also carries an animal-tissue origin — it is made from calf thymus, which raises theoretical transmissible-agent concerns that do not apply to synthetic peptides, and which pharmaceutical manufacture under regulatory inspection exists specifically to control. This page does not recommend, rank, or link any vendor; identity and purity in this market are unverifiable.

Safety

Thymalin is reported as well tolerated in the small Russian studies that exist, but absence of reported harm is not evidence of safety — those studies were not designed as safety trials, no independent pharmacovigilance exists anywhere, and outside Russia this is an injected animal-tissue extract whose composition cannot be verified.

Safety at a Glance

❔ Toxicity unknownDrug interactionsAllergy risk

• Contraindicated in pregnancy and breastfeeding by default. No reproductive data of any kind — see the box below.
• Unpredictable immune effects are mechanistically plausible. A concern with autoimmune disease, transplant or immune-active therapy, and never characterized in a controlled study.
• Procedural risks dominate the pharmacological ones. Injection-site reactions, abscess, endotoxin reaction and bloodborne infection from non-sterile powder.
• Interactions not assessed. No controlled interaction studies exist; treat risk as unknown with immunosuppressants, biologics or chemotherapy.
• Identity cannot be confirmed. As an extract rather than a defined molecule, it fails the testing that works for single-sequence peptides.
• No established dose ceiling. No dose-finding or dose-escalation study has been published.

Full Safety & Interactions Detail

Overall posture. In the small human studies that exist, thymalin was reported as well tolerated with no attributed adverse events ^{1,2Reference 1Khavinson VKh · 2003Peptides of pineal gland and thymus prolong human life — human (long-term controlled study, 266 subjects, no reported randomisation or blinding)View study →Reference 2Kuznik BI et al. · 2022RCTMorphological composition and indicators of the blood clotting system in severe COVID-19 patients of middle and elderly age during treatment with tocilizumab and thymalin — human (comparative, non-randomised)View study →}. That statement is worth very little on its own: those studies were not designed or powered as safety trials, they come from one research network, there is no independent pharmacovigilance anywhere in the world monitoring this compound, and no Western regulator has ever reviewed a safety dossier for it. Decades of Russian clinical use are described as uneventful, but described by the people who developed it, in a literature most readers cannot audit. Do not read the absence of reported harm as evidence of safety.

Injection- and product-specific risks. Because thymalin is injected and, outside Russia, unregulated, the most concrete hazards are procedural rather than pharmacological: injection-site reactions, abscess, endotoxin reaction, and bloodborne infection from non-sterile powder or reconstitution. For a preparation whose composition cannot be verified, the risk of receiving something other than what the vial claims is not hypothetical.

Mechanism-based concerns (unstudied). Thymalin’s whole purpose is to modulate immune function. In anyone who is immunosuppressed, has an autoimmune disease, has had a transplant, or is taking immune-active therapy, an unpredictable immune effect is a mechanistically plausible concern — and it has never been characterized in a controlled study. The radiation-cytogenetics work is a caution in the same spirit: it found thymalin could be protective or sensitizing depending on conditions ^{13Reference 13Domina EA · 2016ReviewChornobyl catastrophe: cytogenetic effects of low dose ionizing radiation and their modification — ex vivo (human lymphocytes) + reviewView study →}, which is a reminder that “immunomodulator” is not a synonym for “immune booster” and that direction of effect is not guaranteed.

Dose-limiting effect. None established — no dose-finding or dose-escalation study has been published.

Interactions. Not assessed. No controlled drug-interaction studies exist. The only co-administration in the literature is with other Khavinson peptides (epithalamin, in the longevity study ^{1Reference 1Khavinson VKh · 2003Peptides of pineal gland and thymus prolong human life — human (long-term controlled study, 266 subjects, no reported randomisation or blinding)View study →}) — a study-design choice, not an interaction assessment. Anyone on immunosuppressants, biologics, or chemotherapy should treat interaction risk as unknown; note that in the one experiment combining thymalin with a chemotherapeutic, the combination did not improve the drug’s effect ^{12Reference 12Baumgart J et al. · 1989AnimalAge-dependent antileukemic action and suppression of immune response by ambazone in mice — animal (mouse); null result for thymalin combinationView study →}.

Who should avoid it. Anyone who is pregnant, breastfeeding, or trying to conceive; anyone with autoimmune disease, a transplant, or on immunosuppressive or immune-modulating therapy; anyone with a known sensitivity to bovine-derived products; and anyone who cannot guarantee sterile sourcing and reconstitution — which, given the supply chain, is nearly everyone acquiring it outside Russia. The conservative position is that it should not be self-administered.

Scope disclosure (honesty, not a claim):

• Human data? Limited and single-network — one long-term cohort with no reported randomization, one unindexed and unregistered randomized COVID-19 trial, one indexed comparative study, and a few small uncontrolled series. No registered trial exists anywhere.
• Interactions assessed? No — no controlled interaction studies. Treat as unknown, especially with immune-active drugs.
• Pregnancy/lactation assessed? No — no data; avoid.
• Long-term safety established? No. Decades of Russian clinical use are reported as safe, but without independent long-term follow-up or any pharmacovigilance system.
• Product identity verifiable? No — and uniquely so. As an extract rather than a defined molecule, thymalin cannot be confirmed by the identity testing that works for single-sequence peptides.

Never imply safety from silence. Where thymalin has not been studied — interactions, pregnancy, long-term use, subcutaneous dosing, gray-market product identity — the correct statement is “not assessed,” not “safe.”

Pregnancy & Lactation

? Not established in pregnancy? Not established in lactation

Not assessed / not established. There are no human pregnancy or lactation data and no adequate reproductive-toxicity studies in the accessible literature, and no label statement exists outside its region of origin. Treat as contraindicated by default in pregnancy and breastfeeding.

Dosage

There is no established Western human dose for thymalin, and none is recommended here. It has no Western approval, no registered trial, and no published dose-finding study; every figure below is reported study data given for context, not a protocol or a personal recommendation.

The Russian clinical literature dosed thymalin in short intramuscular courses rather than continuously. The COVID-19 trial described above used 10 mg IM daily for 10 days on top of standard care, and the long-term geroprotection study administered courses periodically over the first 2–3 years of follow-up ^{1Reference 1Khavinson VKh · 2003Peptides of pineal gland and thymus prolong human life — human (long-term controlled study, 266 subjects, no reported randomisation or blinding)View study →}. That gives a practical picture of roughly 10 mg/day IM for 5–10 days, repeated at intervals — but it comes from unregistered studies at a single research network, and there is no dose-response work behind it, no comparison of course lengths, and no evidence that more is better.

Two specific cautions. First, the dose is expressed in milligrams of an extract, not of a defined active molecule, so “10 mg” only means something relative to a standardized preparation — which gray-market product is not. Second, the studied route is intramuscular; the subcutaneous dosing common in community practice has never been studied for this compound, so those figures cannot be assumed to transfer. There is no oral dose, because there is no oral route that works (see Pharmacokinetics). This entry is informational only.

References

1. Khavinson VKh, Morozov VG. (2003). Peptides of pineal gland and thymus prolong human life — human (long-term controlled study, 266 subjects, no reported randomisation or blinding). Neuro Endocrinol Lett. https://pubmed.ncbi.nlm.nih.gov/14523363/
2. Kuznik BI, et al. (2022). Morphological composition and indicators of the blood clotting system in severe COVID-19 patients of middle and elderly age during treatment with tocilizumab and thymalin — human (comparative, non-randomised). Adv Gerontol. https://pubmed.ncbi.nlm.nih.gov/36169363/
3. Khavinson VK, et al. (2021). Results and prospects of using activator of hematopoietic stem cell differentiation in complex therapy for patients with COVID-19 — human (uncontrolled complex-therapy report). Stem Cell Rev Rep. https://pubmed.ncbi.nlm.nih.gov/33575961/
4. Khavinson VK, et al. (2020). Thymalin: activation of differentiation of human hematopoietic stem cells — in vitro (human cells). Bull Exp Biol Med. https://pubmed.ncbi.nlm.nih.gov/33237528/
5. Linkova N, et al. (2023). The influence of KE and EW dipeptides in the composition of the thymalin drug on gene expression and protein synthesis involved in the pathogenesis of COVID-19 — in vitro (human PBMC) + in silico. Int J Mol Sci. https://pubmed.ncbi.nlm.nih.gov/37686182/
6. Avolio F, et al. (2022). Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line — in vitro (human cell line). Int J Mol Sci. https://pubmed.ncbi.nlm.nih.gov/35408963/
7. Morozov VG, Khavinson VK. (1997). Natural and synthetic thymic peptides as therapeutics for immune dysfunction — review + uncontrolled human clinical use. Int J Immunopharmacol. https://pubmed.ncbi.nlm.nih.gov/9637345/
8. Khavinson VKh. (2002). Peptides and ageing — review. Neuro Endocrinol Lett. https://pubmed.ncbi.nlm.nih.gov/12374906/
9. Zhukova GV, et al. (2018). Effect of Thymalin on the tumor and thymus under conditions of activation therapy in vivo — animal (rat, sarcoma 45). Bull Exp Biol Med. https://pubmed.ncbi.nlm.nih.gov/29797130/
10. Bakhidze EV, Bokhman JaV. (1990). Application of thymic factor “Thymalin” in complex treatment of endometrial cancer patients — human (uncontrolled adjunct series). Eur J Gynaecol Oncol. https://pubmed.ncbi.nlm.nih.gov/2245808/
11. Baumgart J, Zippel D. (1991). Age-dependent experimental tumor dissemination of murine melanoma B16 — animal (mouse); null result for thymalin. Arch Immunol Ther Exp (Warsz). https://pubmed.ncbi.nlm.nih.gov/1841547/
12. Baumgart J, et al. (1989). Age-dependent antileukemic action and suppression of immune response by ambazone in mice — animal (mouse); null result for thymalin combination. Neoplasma. https://pubmed.ncbi.nlm.nih.gov/2770926/
13. Domina EA. (2016). Chornobyl catastrophe: cytogenetic effects of low dose ionizing radiation and their modification — ex vivo (human lymphocytes) + review. Exp Oncol. https://pubmed.ncbi.nlm.nih.gov/28230819/
14. Boiko AA, Malanchuk VA, Myroshnychenko MS. (2024). Reparative osteogenesis in mandible in cases of filling a bone defect with hydroxyapatite-containing osteotropic material and thymalin — animal (rat). Wiad Lek. https://pubmed.ncbi.nlm.nih.gov/38431810/
15. Boiko AA, et al. (2024). Expression features of T-lymphocytes, B-lymphocytes and macrophages in the post-traumatic regenerate of the mandible in rats treated with thymalin — animal (rat). Pol Merkur Lekarski. https://pubmed.ncbi.nlm.nih.gov/38642352/
16. Litvinenko GI, et al. (2015). Chrono- and immunocorrection of inflammatory disorders of internal reproductive organs in women of reproductive age — human (small clinical trial). Bull Exp Biol Med. https://pubmed.ncbi.nlm.nih.gov/26033592/

View all 16 references▾